CAMPBELL, Calif., May 19, 2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin, announced the appointment of Natalie Brunell to its board of directors. This strategic addition reflects Semler Scientific's continued commitment to its Bitcoin treasury strategy and further strengthens its leadership within the Bitcoin community.
"We are thrilled to welcome Natalie to our board of directors," said Eric Semler, chairman of Semler Scientific. "Natalie is a highly respected journalist and educator – and a leading advocate for Bitcoin, with a deep understanding of its role as a transformative asset. As the 4th largest U.S. public company on the Bitcoin Standard in terms of Bitcoin holdings, we believe we are a strategic asset. Her insights will be instrumental as we pursue our Bitcoin treasury strategy and aim to deliver long-term value to our stockholders."
"I am honored to join Semler Scientific's board at such an exciting time in the company's journey," said Natalie Brunell, board member of Semler Scientific. "As one of the leaders in adopting Bitcoin as a primary treasury reserve asset, Semler Scientific's innovative approach sets a powerful example for companies globally. I look forward to contributing to the continued growth and success of the company's Bitcoin strategy, and helping shape the future of corporate treasury management in the digital age."
About Natalie Brunell
Natalie Brunell shines in the Bitcoin space as a top-rated podcast host, influential educator, and poised media commentator. As the leading Bitcoin podcast, 'Coin Stories' is a deep, engaging dive into the revolutionary Bitcoin network and how it intersects with global economics and technology trends. Natalie's incisive interviews do more than just explore the nuances of finance; they reveal the human element behind the headlines, offering a compelling narrative about the relentless pursuit of the American Dream in the digital age.
Previously, Natalie was an award-winning TV journalist and investigative reporter. For more than 10 years she covered in-depth local and national news topics and holds a regional news Emmy for breaking news coverage.
Natalie was also an adjunct professor of advanced communication and visual storytelling at the University of Southern California. She holds a Master's of Science in Journalism from Northwestern University.
About Semler Scientific, Inc.
Semler Scientific, Inc. is a publicly traded company that has adopted Bitcoin as its primary treasury reserve asset and is one of the leading corporate holders of Bitcoin. In May 2024, Semler Scientific became the second U.S. publicly traded company to adopt a Bitcoin treasury strategy. By using proceeds from equity and debt financings, as well as cash flows from operations, Semler Scientific intends to strategically accumulate Bitcoin. In addition, through its healthcare business, Semler Scientific is a pioneer in developing and marketing technology products and services to assist its customers in evaluating and treating chronic diseases. Its flagship product, QuantaFlo®, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). Additional information about Semler Scientific can be found at www.semlerscientific.com.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$44.93 |
Daily Change: | 0.04 0.09 |
Daily Volume: | 2,369,119 |
Market Cap: | US$416.500M |
May 13, 2025 February 18, 2025 January 23, 2025 November 04, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load